Abstract Background Multiple Sclerosis (MS) is a neuroinflammatory disorder which affects
2.8 million people world-wide. A growing body of evidence shows ethnic disparities in MS …

Introduction This study assessed the societal costs of multiple sclerosis (MS) in Lebanon,
categorized by disease severity. Methods This was a cross-sectional, prevalence-based …

Background Multiple sclerosis (MS) management varies markedly between different
countries of the Middle East and North Africa (MENA) region based on the availability and …

Background Multiple sclerosis (MS) is the most common demyelinating disease of the
central nervous system, and the major neurologic cause of disability in young adults. Its …

Background Multiple sclerosis (MS) is a chronic and progressive neurological autoimmune
disease that affects the central nervous system. There are two types of drugs used to treat …

Multiple sclerosis (MS) is a demyelinating disease of the central nervous system, which is a
primary cause of neurological disability in young and middle‐aged individuals in …

Background Multiple sclerosis (MS) is a chronic autoimmune disease that causes
progressive functional impairment, mainly in walking tasks. Noninvasive brain stimulation …

Background Multiple sclerosis (MS) is an autoimmune demyelinating disease that involves
the central nervous system (CNS). Individuals with Multiple Sclerosis (MS) may experience …

Background Disease-related knowledge of people with multiple sclerosis (MS) can influence
self-management, co**, treatment adherence, and clinical health outcomes. Studies …

Fatigue is one of the most prevalent and disabling symptoms among patients with MS, but
there is limited research investigating the longitudinal determinants of fatigue progression …